The development of RNA sequencing (RNA-Seq) technologies has significantly expanded the capabilities of RNA-based biomolecules for use in diagnosis, prognosis, and therapeutic strategies across various medical fields, including oncology and infectious disease management. RNA-Seq technology excels in detecting gene fusions and variably expressed transcripts associated with diseases, providing immediate and valuable insights. More significantly, RNA-Seq’s ability to identify a wide range of RNA species paves the way for innovative clinical applications. One of the most promising uses is employing extracellular RNAs as non-invasive biomarkers for disease diagnosis, offering a less intrusive option compared to traditional methods. Concerted efforts in several key areas are further enhancing RNA-Seq’s clinical impact: developing benchmark standards, refining assays for compatibility with clinical workflows, and ensuring the consistency and reproducibility of these assays. These initiatives aim to establish a robust framework for the broader adoption of RNA-Seq in clinical settings. By addressing these technical and regulatory challenges, researchers and clinicians can leverage RNA-Seq to unlock a new era of precision medicine, where RNA-based diagnostics and treatments are tailored to individual patient profiles, enhancing the efficacy and efficiency of medical interventions.